Shkreli inflated price of life-saving drug from federal prison, FTC says

Martin Shkreli conspired to illegally increase the price of a life-saving drug during phone calls he made from prison, according to the US Federal Trade Commission (FTC).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Celgene, Teva execs grilled over price hikes

1 October 2020 A US House of Representatives committee has accused Teva and Celgene of imposing unjustified price hikes on blockbuster drugs Copaxone and Revlimid.

Big Pharma

Judge issues mixed ruling on Shkreli attorney communications

21 August 2020 The FTC should avoid reviewing communications between Martin Shkreli and his attorneys, but these are not protected under the Privacy Act, a New York federal judge has ruled.

Americas

Shkreli says he isn’t responsible for Daraprim ‘monopoly’

30 July 2020 Jailed ‘pharma bro’ Martin Shkreli has told a US federal court he is not responsible for antitrust violations alleged by the US Federal Trade Commission.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Shkreli inflated price of life-saving drug from federal prison, FTC says

More on this story

Editor's picks

Editor's picks

More features